Biotech Scan
Scan
Biotech Scan
raw scan snapshot — prices as of scan date, not live 56 rows · screens, not recommendations
Biotech is in a full risk-on melt-up — the sector ETFs are all breaking out (XBI RSI 73, IBB RSI 71, LABU +42.5% 30D) and the small/mid-cap complex is running hard. This is the cleanest CONFIRMED-BREAKOUT sleeve in the batch: gene-editing (BEAM +47.1% 3M, NTLA +25.5% 30D), specialty/rare-disease (PTGX, RARE, COGT, INCY), and mRNA (MRNA +25.9% 30D) all golden-cross + above SMA200. The few laggards (REGN, SRPT, ALNY) are the structurally-broken names. Entry-frame: the breakout is real but several leaders are RSI 70+; chase the basing names, don't pay up for the parabolic ones (KYMR RSI 84).
Source: biotech-scan.json. Latest bar 2026-06-25.
Quick Snapshot
| Signal | Reading |
|---|---|
| Overall | 🟢 Sector-wide breakout — XBI/IBB/LABU all up + above SMA200; small/mid biotech running. Risk-on confirmed, but leaders extended (RSI 70+); favor basing names over chasing |
| Leaders | KYMR (RSI 84, +44.4% 30D, parabolic), LABU (RSI 74, +42.5% 30D), XBI (RSI 73, breakout), PTGX (RSI 73, near ATH), RARE (RSI 71, +26.4% 30D), ILMN (RSI 71, +24.6% 30D), ABBV (RSI 72, +14% 30D) |
| Laggards | SRPT (RSI 42, -26.1% 3M, collapse), REGN (RSI 44, -17.9% 3M, strong-down), ALNY (RSI 50, -11% 3M, collapse), GILD (RSI 42, -8.6% 3M), LEGN (RSI 45, below SMA20) |
| Key insight | Gene-editing trio re-rating in lockstep (BEAM +47.1% 3M, NTLA +25.5% 30D, CRSP +15% 3M) — the highest-beta corner of the sector confirming the risk-on bid; this is a clean breakout cohort, but BEAM/KYMR are already extended |
Price Table
| Stock | Price | RSI | vs SMA20 | 7D% | 30D% | 3M% | 52wkHi% | Signal |
|---|---|---|---|---|---|---|---|---|
| ISRG | $400.52 | 37.6 ↓ | -2.8% | -1.02% | -8.27% | -14.52% | -33.68% | ❌ Don't Buy (collapse) |
| SRPT | $16.02 | 42.1 ↓ | -2.4% | -3.53% | -3.90% | -26.11% | -36.73% | ❌ Don't Buy (collapse) |
| GILD | $124.29 | 42.2 ↓ | -1.9% | +1.63% | -6.45% | -8.60% | -20.98% | 🔍 Watch |
| REGN | $620.14 | 43.9 ↓ | +0.9% | +3.91% | -2.28% | -17.93% | -24.48% | ❌ Don't Buy (strong-down) |
| NKTR | $62.15 | 44.2 ↓ | +2.0% | +7.72% | -5.20% | -12.43% | -42.98% | 🔍 Watch (below SMA50) |
| LEGN | $28.81 | 45.3 ↓ | -9.9% | +1.56% | -2.44% | +64.72% | -36.40% | 🔍 Watch (GC, below SMA20) |
| BNTX | $90.15 | 48.0 | +0.2% | -0.60% | -2.28% | +3.08% | -27.30% | 🔍 Watch (strong-down) |
| ALNY | $291.93 | 49.6 | +0.1% | +6.54% | -1.21% | -11.04% | -41.09% | ❌ Don't Buy (collapse) |
| RXRX | $3.34 | 52.9 | +0.3% | +3.85% | +12.46% | +6.03% | -53.48% | 🔍 Watch (spec, downtrend) |
| EDIT | $2.86 | 53.5 | +3.0% | +7.66% | -7.14% | +23.28% | -37.07% | 🔍 Watch (spec) |
| MDT | $81.29 | 56.0 | +2.7% | +2.00% | +4.76% | -6.52% | -23.55% | 🔍 Watch |
| CRSP | $54.69 | 56.4 | +3.1% | +0.66% | +6.01% | +15.02% | -30.31% | 🔍 Watch (weak-up, below SMA200) |
| BMRN | $57.21 | 58.4 | +2.5% | +4.52% | +8.19% | +2.99% | -13.69% | 🔍 Watch (up) |
| BIIB | $204.40 | 60.1 | +3.8% | +2.53% | +5.86% | +6.98% | -1.09% | 🔒 Hold (uptrend, near ATH) |
| AMGN | $355.86 | 60.5 | +3.5% | +4.40% | +5.93% | +1.53% | -9.05% | 🔒 Hold (basing) |
| LLY | $1,127.69 | 60.6 | +0.9% | +1.55% | +5.91% | +25.93% | -4.65% | 🔒 Hold (uptrend) |
| BEAM | $34.75 | 60.7 | +10.0% | +3.11% | +16.65% | +47.12% | -5.78% | 📈 Accumulate (GC, +27.3% vs SMA200) |
| INCY | $107.27 | 61.0 | +5.6% | +12.46% | +10.47% | +16.27% | -4.47% | 📈 Accumulate (uptrend, near ATH) |
| MRNA | $59.21 | 61.2 | +12.9% | -2.28% | +25.90% | +10.53% | -12.60% | 📈 Accumulate (+48.3% vs SMA200) |
| NTLA | $15.82 | 61.4 | +12.3% | +2.58% | +25.46% | +19.49% | -43.98% | 📈 Accumulate (GC, +16.8% vs SMA200) |
| DNA | $9.77 | 63.3 | +11.6% | +8.09% | +12.43% | +52.42% | -44.43% | 🔍 Watch (spec, +52% 3M) |
| TMO | $505.75 | 64.0 | +5.7% | +6.73% | +12.96% | +3.56% | -21.47% | 🔍 Watch (weak-up, below SMA200) |
| A | $137.18 | 64.9 | +3.7% | +4.44% | +19.20% | +21.16% | -14.41% | 📈 Accumulate (up) |
| IONS | $79.04 | 65.6 | +5.6% | +3.48% | +3.90% | +6.47% | -8.88% | 🔒 Hold (basing) |
| NVO | $47.46 | 66.2 | +7.5% | +10.46% | +7.40% | +35.18% | -33.91% | 🔍 Watch (pullback, -34% from ATH) |
| DHR | $194.65 | 67.8 | +6.9% | +6.45% | +12.64% | +3.73% | -19.83% | 🔍 Watch (weak-up, below SMA200) |
| VRTX | $480.18 | 69.2 | +6.8% | +4.79% | +10.15% | +5.83% | -5.46% | 🔒 Hold (basing) |
| IBBQ | $31.59 | 69.7 | +6.4% | +5.10% | +7.56% | +11.27% | -1.47% | ⚠️ Approaching OB (breakout) |
| COGT | $38.28 | 70.6 | +13.1% | +9.06% | +12.79% | +3.82% | -12.46% | ⚠️ Approaching OB (uptrend) |
| ILMN | $180.91 | 70.6 | +9.9% | +8.79% | +24.57% | +45.43% | -1.06% | ⚠️ Approaching OB (near ATH) |
| IBB | $184.10 | 70.7 | +7.0% | +5.26% | +8.68% | +11.41% | -1.45% | ⚠️ Approaching OB (breakout) |
| RARE | $29.25 | 71.4 | +18.0% | +6.12% | +26.40% | +46.25% | -30.97% | ⚠️ Approaching OB (+18% vs SMA20) |
| ABBV | $242.86 | 71.5 | +8.3% | +8.02% | +13.95% | +15.99% | -0.80% | ⚠️ Approaching OB (breakout, ATH) |
| PTGX | $122.93 | 72.9 | +14.9% | +8.54% | +22.95% | +20.32% | -2.58% | ⚠️ Approaching OB (uptrend) |
| XBI | $151.59 | 73.0 | +11.3% | +7.32% | +13.79% | +22.47% | -2.01% | ⚠️ Approaching OB (breakout) |
| LABU | $258.54 | 73.8 | +35.1% | +23.47% | +42.46% | +66.79% | -5.11% | ⚠️ Don't chase (3x ETF, extended) |
| KYMR | $116.62 | 83.9 ↑ | +37.2% | +10.39% | +44.39% | +45.45% | -10.33% | ⚠️ Extended/Trim (parabolic) |
Tier Analysis
Oversold / Breaking Down (RSI < 50)
- SRPT ($16.02, RSI 42) — Sarepta: collapse regime, -26.1% 3M, -36.7% from ATH, death-cross, -18.6% vs SMA200. Gene-therapy de-rating; falling knife. BROKEN/AVOID.
- REGN ($620.14, RSI 44) — Regeneron: strong-down, death-cross, -17.9% 3M, -24.5% from ATH, -11% vs SMA200. Eylea franchise pressure; no entry despite the sector bid passing it by. BROKEN/AVOID.
- GILD ($124.29, RSI 42) — Gilead: pullback, -6.5% 30D, -21% from ATH, below all 3 SMAs. Golden cross intact (technical) but trend is down; watch for RSI < 40 capitulation, not here.
- LEGN ($28.81, RSI 45) — Legend Bio: +64.7% 3M but pulled back -9.9% below SMA20 this leg; golden cross + above SMA200. Digesting a big run; NEUTRAL — watch for the flag to resolve up.
- ALNY ($291.93, RSI 50) — Alnylam: collapse regime, -11% 3M, -41.1% from ATH, death-cross, -21.3% vs SMA200. RNAi leader still de-rating. BROKEN/AVOID despite the +6.5% 7D bounce.
Breakout / Leading (RSI 56–66) — CONFIRMED-BREAKOUT cohort
- BEAM ($34.75, RSI 61) — Beam Therapeutics: strong-up, golden cross, +47.1% 3M, +27.3% vs SMA200, -5.8% from ATH. CONFIRMED-BREAKOUT — cleanest gene-edit name; +10% above SMA20 so wait for a flag, don't chase the vertical.
- NTLA ($15.82, RSI 61) — Intellia: strong-up, golden cross, +25.5% 30D, +19.5% 3M, +16.8% vs SMA200. CONFIRMED-BREAKOUT but -44% from ATH = lots of overhead. Earliest-innings of the trio.
- CRSP ($54.69, RSI 56) — CRISPR Tx: weak-up, +15% 3M, +3.1% vs SMA20 but still -1.5% below SMA200 and death-cross. The laggard of the gene-edit trio; needs to reclaim SMA200 to confirm. NEUTRAL.
- MRNA ($59.21, RSI 61) — Moderna: strong-up, golden cross, +25.9% 30D, +48.3% vs SMA200, +118% 1Y, -12.6% from ATH. CONFIRMED-BREAKOUT — mRNA re-rating confirmed across biotech + healthcare scans. Best large-cap momentum name; -2.3% 7D = mild flag, accumulate on the pullback.
- INCY ($107.27, RSI 61) — Incyte: strong-up, golden cross, +16.3% 3M, +12.5% 7D, near ATH. CONFIRMED-BREAKOUT, clean.
- BIIB ($204.40, RSI 60) — Biogen: uptrend, golden cross, +16.2% vs SMA200, near ATH (-1.1%). Alzheimer's re-rate holding. Hold.
- LLY ($1,127.69, RSI 61) — Eli Lilly: uptrend, golden cross, +25.9% 3M, +16.1% vs SMA200, -4.7% from ATH. The sector's premier compounder. Hold.
Momentum / Extended (RSI 67–84) — EXTENDED/TRIM territory
- VRTX ($480.18, RSI 69) — Vertex: basing→up, +10.2% 30D, -5.5% from ATH. Approaching extended; hold if owned, don't initiate.
- ABBV ($242.86, RSI 72) — AbbVie: breakout regime, +16% 3M, at ATH (-0.8%), +11.1% vs SMA200. Strong, but RSI 72 + at ATH = EXTENDED/TRIM; wait for a pullback to add.
- PTGX ($122.93, RSI 73) — Protagonist: strong-up, +23% 30D, near ATH, +38.6% vs SMA200. Extended; great trend, bad entry.
- RARE ($29.25, RSI 71) — Ultragenyx: +26.4% 30D, +18% above SMA20. Sharp spike — EXTENDED, let it cool.
- ILMN ($180.91, RSI 71) — Illumina: strong-up, +45.4% 3M, +41.2% vs SMA200, near ATH. Huge run; EXTENDED/TRIM — don't chase at ATH.
- KYMR ($116.62, RSI 84) — Kymera: parabolic, +44.4% 30D, +56% vs SMA200, +37% above SMA20. EXTENDED/TRIM — textbook overbought; do not chase, trim into strength if held.
- LABU ($258.54, RSI 74) — 3x leveraged biotech ETF: +42.5% 30D, +66.8% 3M. Leverage decay makes this a trade not a hold; the move confirms sector strength but don't chase.
Entry Zones
| Stock | Price | Zone | RSI | 30D% | Setup |
|---|---|---|---|---|---|
| MRNA | $59.21 | <$57 | 61.2 | +25.9% | mRNA re-rating; +48.3% vs SMA200; GC; -2.3% 7D flag = add the dip |
| BEAM | $34.75 | <$33 | 60.7 | +16.7% | Cleanest gene-edit breakout; GC; +27.3% vs SMA200; wait for flag near SMA20 |
| NTLA | $15.82 | <$15 | 61.4 | +25.5% | Earliest-innings gene-edit; GC; -44% from ATH = runway; add on pullback |
| INCY | $107.27 | <$104 | 61.0 | +10.5% | Strong-up + near ATH; GC; clean breakout; buy SMA20 retest |
| CRSP | $54.69 | <$52 | 56.4 | +6.0% | Gene-edit laggard; needs to reclaim SMA200; probe only on confirmation |
Action Matrix
| Action | Stocks | Why |
|---|---|---|
| 🔒 HOLD | LLY, BIIB, AMGN, VRTX, IONS | Trends/theses intact; large-cap anchors near ATH; don't sell strength |
| 📈 ACCUMULATE | MRNA, BEAM, NTLA, INCY, A | Confirmed breakouts, golden cross, above SMA200; buy flags not vertical legs |
| 🔍 WATCH | CRSP, LEGN, BMRN, NVO, TMO, DHR, NKTR | Basing/laggards with intact-ish setups; wait for SMA200 reclaim / RSI confirm |
| ⚠️ EXTENDED / DON'T CHASE | KYMR, ABBV, PTGX, RARE, ILMN, COGT, XBI, IBB, LABU | RSI 70-84 and/or at ATH; great trends, bad entries — wait for pullback |
| ❌ DON'T BUY | SRPT, REGN, ALNY, ISRG | Collapse / strong-down + death-cross; structural de-rates not finished |
What Changed
- Sector-wide breakout — XBI (RSI 73, breakout), IBB (RSI 71, breakout), LABU (+42.5% 30D) all confirming. Biotech is the cleanest risk-on sleeve in the batch.
- Gene-editing trio re-rating — BEAM (+47.1% 3M), NTLA (+25.5% 30D), CRSP (+15% 3M) moving together; BEAM/NTLA confirmed (above SMA200), CRSP still the laggard (below SMA200).
- MRNA dual-scan confirmation — +25.9% 30D, +48.3% vs SMA200; shows in both biotech and healthcare scans. Most significant large-cap inflection.
- KYMR parabolic (RSI 84) — Kymera +44.4% 30D into extreme overbought; the sector's hottest hand and the clearest don't-chase.
- Laggard cohort isolated — SRPT (-26% 3M), REGN (-18% 3M), ALNY (-11% 3M) are the structurally-broken names the breakout left behind; all death-cross.
Key Discoveries
| Discovery | Implication |
|---|---|
| XBI/IBB/LABU all breaking out together | Sector-wide risk-on bid, not single-name noise — the regime is buy-biotech |
| Gene-edit trio moving in lockstep, CRSP lagging | High-beta corner confirming; CRSP's SMA200-reclaim is the tell for the laggard trade |
| Leaders clustered RSI 70-84 at/near ATH | Breakout is mature, not early — entry edge is in the basing names, not the leaders |
Mistakes (Don't Repeat)
| Mistake | Lesson |
|---|---|
| Chasing KYMR/LABU at RSI 84/74 | Parabolic + 3x-leveraged = the move is mostly behind you; wait for the flag |
| Buying GILD/REGN's "golden cross" tag as a dip | Engine GC flag ≠ trend; both are below SMA200 / strong-down — falling knives |
Open Questions
Related
10 eventsNo direct external sources are attached to this read.